Learn­ing from oth­er­s' mis­takes, low-pro­file mi­croR­NA biotech looks to prove it­self in the clin­ic

The same year that Al­ny­lam and Isis — long be­fore it was re­named Io­n­is — spun out their mi­croR­NA re­search in­to Reg­u­lus Ther­a­peu­tics, an on­col­o­gy-fo­cused VC in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER